Yousif Capital Management LLC Acquires New Shares in Natera, Inc. $NTRA

Key Points

• Yousif Capital Management LLC has acquired 1,610 shares of Natera, Inc., valued at approximately $272,000, marking a new investment in the medical research company.
• Natera reported a loss of $0.74 per share in its recent quarterly earnings, missing analysts' expectations, although its revenue increased by 32.2% year-over-year.
• Several analysts have adjusted their price targets for Natera, with Piper Sandler raising its target to $220.00, reflecting a generally positive outlook from the market.

Yousif Capital Management LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,610 shares of the medical research company's stock, valued at approximately $272,000.

A number of other hedge funds also recently made changes to their positions in the stock. Bank of Jackson Hole Trust acquired a new stake in Natera in the first quarter valued at approximately $29,000. Hilltop National Bank acquired a new stake in shares of Natera during the 2nd quarter valued at $33,000. Oliver Lagore Vanvalin Investment Group bought a new stake in Natera during the 2nd quarter worth $36,000. TCTC Holdings LLC increased its holdings in Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company's stock worth $33,000 after purchasing an additional 124 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of Natera by 83.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company's stock valued at $33,000 after purchasing an additional 106 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Up 3.7%

Natera stock opened at $195.00 on Friday. The company has a market capitalization of $26.76 billion, a PE ratio of -102.09 and a beta of 1.74. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $196.63. The firm's fifty day moving average is $170.70 and its 200 day moving average is $159.76.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company's revenue for the quarter was up 32.2% on a year-over-year basis. During the same period last year, the firm posted ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. Sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent research reports. Piper Sandler restated an "overweight" rating and issued a $220.00 price target (up from $210.00) on shares of Natera in a research report on Monday, August 11th. Canaccord Genuity Group reiterated a "buy" rating and issued a $200.00 price target on shares of Natera in a research report on Tuesday, October 14th. Morgan Stanley restated an "overweight" rating and set a $195.00 price objective on shares of Natera in a research report on Sunday, August 10th. Wells Fargo & Company began coverage on Natera in a report on Monday, September 22nd. They issued an "equal weight" rating and a $175.00 target price on the stock. Finally, Cowen restated a "buy" rating on shares of Natera in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus target price of $197.59.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 292 shares of the business's stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40. Following the completion of the sale, the insider owned 117,267 shares in the company, valued at approximately $22,040,332.65. The trade was a 0.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Michael Burkes Brophy sold 602 shares of the company's stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $187.95, for a total transaction of $113,145.90. Following the transaction, the chief financial officer owned 70,109 shares in the company, valued at approximately $13,176,986.55. The trade was a 0.85% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 70,276 shares of company stock worth $10,794,948. Insiders own 5.63% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.